Abstract:Background: Vincristine is a potent therapeutic agent with well-defined activity against hematologic malignancies and solid tumors. It is a cell-cycle specific drug with concentration and exposure duration dependent activity. When used by liposomal delivery, it exhibits enhanced anti-tumor activity. However, vincristine liposome formulation in the clinic is supplied as a 3-vial-kit due to lacking sufficient stability. So it has to be prepared in situ prior to use through a multi-step process. Purpose: The purpose here is to develop a more stable and ready-to-use liposomal formulation for vincritstine in one vial. Patients and methods: A series of preparations were investigated based on sphingomyelin/cholesterol/PEG2000-DSPE lipid composition, with different drug/lipid (D/L) ratios (1/10, 1/5, 1/2), using an active sucrose octasulfate triethylamine salt gradient loading method. In this work, compared to generic vincristine sulfate liposome injection (GVM), the stability both in vivo and in vitro and efficacy in vivo of novel vincristine liposomes were investigated. Results: It was shown that the degradation of vincristine during 2-8°C storage was significantly decreased from 8.2% in 1 month (GVM) to 2.9% in 12 months (D/L ratio 1/5). The half-time for sphingomyelin/cholesterol/PEG2000-DSPE liposomes in vivo could be adjusted from 17.4 h (D/L ratio 1/10) to 22.7 h (D/L ratio 1/2) in rats, while the half-time for GVM was only 11.1 h. The increase in drug retention contributed to the lower in vivo toxicity. The antitumor efficacy was evaluated using a human melanoma tumor model and showed remarkable improvement compared to GVM. Conclusion: The study demonstrates that the new formulation with the drug/lipid ratio of 1/5 owns a higher encapsulation efficiency, better stability, lower toxicity and superior antitumor efficacy, which is screened out for further development.

Selection of transdermal drug delivery system for vincristrine and research on the transdermal mechanism

[Preparation of Transfersomes of Vincristine Sulfate and Study on Its Prcutaneous Penetration].

[Transdermal and Lymph Targeting Transfersomes of Vincristine].

Penetration profile and human cadaver skin distribution of finasteride from vesicular nanocarriers.

Biodegradable Self-Assembled Micelles Based on MPEG-PTMC Copolymers: An Ideal Drug Delivery System for Vincristine

Research on the loading and release kinetics of the vincristine sulfate liposomes and its anti-breast cancer activity

Formulation and Characterization of Spray-Dried Powders Containing Vincristine-Liposomes for Pulmonary Delivery and Its Pharmacokinetic Evaluation From In Vitro and In Vivo

Recent Progress in Transdermal Nanocarriers and Their Surface Modifications

Development of a Ropivacaine-Loaded Nanostructured Lipid Carrier Formulation for Transdermal Delivery

Preparation and in vitro evaluation of vincristine-loaded superparamagnetic iron oxide nanoparticles

The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate

The Study of Improved Controlled Release of Vincristine Sulfate from Collagen-Chitosan Complex Film

Preparation and quality evaluation of vincristine sulfate-loaded PEG-PLGA nanoparticles

Preparation and Characterization of Transfersomes of Three Drugs in Vitro

Vincristine liposomes with smaller particle size have stronger diffusion ability in tumor and improve tumor accumulation of vincristine significantly

Enhanced transdermal delivery of curcumin nanosuspensions: A mechanistic study based on co-localization of particle and drug signals

New progress in transdermal drug delivery

[Preparation of liposome entrapped vincristine sulfate and mitoxantrone chlorhydric acid].

Development of a stable single-vial liposomal formulation for vincristine

Vincristine-doxorubicin co-loaded artificial low-density lipoproteins towards solid tumours

Lipid Nanoparticles Loading Triptolide for Transdermal Delivery: Mechanisms of Penetration Enhancement and Transport Properties.